Indivior’s miracle drug wears off

Indivior’s opioid addiction treatment has been exposed to generic competition. Can the drugmaker fight back? Alice Gråhns reports.

861-indivior-shares-b

Will copycat pills hit Indivior's bottom line?
(Image credit: This content is subject to copyright.)

Indivior's opioid addiction treatment has been exposed to generic competition. Can the drugmaker fight back? Alice Grhns reports.

Subscribe to MoneyWeek

Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE

Get 6 issues free
https://cdn.mos.cms.futurecdn.net/flexiimages/mw70aro6gl1676370748.jpg

Sign up to Money Morning

Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter

Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter

Sign up
Explore More

Alice grew up in Stockholm and studied at the University of the Arts London, where she gained a first-class BA in Journalism. She has written for several publications in Stockholm and London, and joined MoneyWeek in 2017.